Testing a new low-dose combination treatment for high blood pressure
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low dose treatment for hypertension (QUARTET USA)
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-10680465
This study is looking at whether a new treatment using four low-dose medications can help lower high blood pressure better and safer than a standard single medication, and it's for adults with high blood pressure who don't have heart disease.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10680465 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness and safety of a new treatment approach for high blood pressure using a combination of four medications at ultra-low doses. Participants will receive either this new treatment or a standard dose of one medication, and their blood pressure will be monitored over 12 weeks. The goal is to determine if the new treatment can lower blood pressure more effectively without increasing side effects. The study focuses on adults with elevated blood pressure who do not have cardiovascular disease.
Who could benefit from this research
Good fit: Ideal candidates are adults with high blood pressure who do not have existing cardiovascular disease.
Not a fit: Patients with severe cardiovascular disease or those not meeting the blood pressure criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for managing high blood pressure.
How similar studies have performed: Preliminary data from a short-term trial suggest that similar low-dose combination therapies have shown promising results.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUFFMAN, MARK D — WASHINGTON UNIVERSITY
- Study coordinator: HUFFMAN, MARK D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cardiovascular Diseases, cardiovascular disorder